ABSTRACT

This study looks into empagliflozin, a novel type of diabetes drug called sodium–glucose co transporter blockers (SGLTi), as well as its analytical technique. Diabetes is one of the oldest diseases known to man. There are 4 different types of diabetes mellitus: prediabetes, gestational, type 1 diabetes, and type 2 diabetes. Type 2 diabetes was previously known as non-insulin-dependent diabetes or adult-onset diabetes. In persons with type 2 diabetes and existing cardiovascular disease, empagliflozin was the first SGLT2-inhibitor medication to decrease the risk of cardiovascular risk.In terms of pharmacokinetics, Empagliflozin has been rapidly absorbed from the gastrointestinal tract, reaching c max after 1.33–3.0 h and then decreasing in a biphasic fashion, with a mean t12 ranging from 10.3 to 18.8 h, half life(t12) was up to 13.1 h, AUC but also c peak seem to be 89.8 and 70.7, CLR around 72 h varied from 32.1 to 51.3 mL/min, urinalysis (fe) over 72 HPLC-based analytical technique invention, testing of Durability Displaying RP-HPLC,UV,RP-LC.UPLC method with some other pharmaceuticals are among the analytical techniques used in empagliflozin. Empagliflozin has been used in individuals with cardiac arrest to lower the risk of hospitalization and mortality from heart failure. Keywords: Type 2 diabetes (T2D), empagliflozin, pharmacokinetic and pharmacodynamics, RP-HPLC, UV UPLC
Publication date: 01/10/2022

https://ijbpas.com/pdf/2022/October/MS_IJBPAS_2022_6474.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.10.6474